<scp>SARS‐CoV</scp>‐2 infection in a X‐linked agammaglobulinemia adolescent: An immunological approach to treatment

Stracuzzi, Marta; Vanetti, Claudia; Clerici, Mario; Zuccotti, Gian Vincenzo; Trabattoni, Daria; Giacomet, Vania

doi:10.1111/pai.13921

Cited by 1 publication

(1 citation statement)

References 8 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results at T2 and T3 were compared to those obtained from 14 HCs. SARS-CoV-2-specific B and T cells were identified as previously described (27,28). Briefly, frozen PBMCs were thawed and allowed to rest overnight at 37°C in a humidified atmosphere with 5% CO2 in a complete medium characterized by RPMI 1640 (Euroclone, Milan, Italy), supplemented with 10% FBS (Euroclone, Milan, Italy), 2 mM Lglutamine and 100 U/ml penicillin and streptomycin (Life Technologies).…”

Section: Flow Cytometrymentioning

confidence: 99%

Humoral and cell-mediated immune responses in HIV-vertically infected young patients after three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine

Vanetti,

Stracuzzi,

Crivellaro

et al. 2024

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

BackgroundData on the efficacy of three SARS-CoV-2 mRNA BNT162b2 vaccine doses and the role of previous SARS-CoV-2-infection in enhancing vaccine immunogenicity in HIV-vertically-infected people living with HIV (PLWH) are limited, as is the duration of vaccine-induced responses.MethodsSARS-CoV-2 plasma neutralizing activity (NA) against the European (B.1), Delta (B.1.617.2) and Omicron (B.1.1.529) variants and cell-mediated immunity (CMI) were analyzed in 29 ART-treated young PLWH (mean age 27.9 years) and 30 healthy controls (HC) who received three BNT162b2 vaccine doses. Individuals were stratified based on the presence/absence of previous SARS-CoV-2 infection (infected and vaccinated -SIV-; uninfected and vaccinated -SV-). Analyses were performed before vaccination (T0), 25 days from the second dose (T1), the day the third dose was administered (T2), and 3 months after the third dose (T3).ResultsIn PLWH: i) NA against all variants was higher in SIV compared to SV at T2 and was increased at T3; ii) switched-memory plasmablasts were augmented in SIV alone at T2 and T3; iii) a SARS-CoV-2 specific T cell memory was generated; iv) IFN-γ-secreting CD4+ and CD8+ T lymphocytes were boosted at T3 mainly in SV. CMI magnitude was reduced in PLWH compared to HC. Notably, after the third dose of vaccine viremia was unmodified, but CD4 T cell counts were reduced>20% in 3/29 PHLW.ConclusionA third dose of BNT162b2 vaccine induces strong humoral and CMI responses in young ART-treated PLWH independently from a previous SARS-CoV-2 natural infection. The lower magnitude of CMI responses should be considered when planning mRNA vaccine booster doses in PLWH.

show abstract

Section: Flow Cytometrymentioning

confidence: 99%